Assurerx Health

What Assurerx Health does

Assurex Health, Inc. (doing business as Myriad Neuroscience) is a Mason, Ohio-based pharmacogenomic testing company founded in 2009 and operating as a privately-held subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN). The company develops and commercializes the GeneSight test portfolio, which analyzes clinically important genetic variations to inform healthcare providers how patients may metabolize or respond to medications commonly prescribed for depression, anxiety, ADHD, and other psychiatric conditions. Its core products include the GeneSight Psychotropic Test (covering 60+ mental health medications), the GeneSight MTHFR Test, and the GeneSight at Home self-collection kit, all processed at the company's CLIA- and CAP-accredited laboratory.

The underlying technology is a proprietary weighted multi-gene algorithm that integrates pharmacokinetic gene analysis (CYP2D6, CYP3A4, CYP2B6, UGT1A4, CYP2C19, CES1A1, CYP1A2, UGT2B15, CYP2C9) and pharmacodynamic gene analysis (SLC6A4, HLA-A*3101, ADRA2A, HTR2A, HLA-B*1502), with results delivered in approximately three days via a color-coded green/yellow/red report. Assurex Health reports that over 3 million people have taken the GeneSight test and more than 25,000 healthcare professionals have ordered it.

Revenue is generated primarily through laboratory testing services billed to insurance (Medicare, Medicare Advantage, Medicaid, and commercial plans), with a maximum patient out-of-pocket cost capped at $330 (98% of patients pay this or less) and $0 typical cost for Medicare/Medicaid patients. The go-to-market is clinician-directed—tests must be ordered by registered providers through the mygenesight.com portal—supplemented by direct-to-consumer demand generation via a Find-a-Provider directory, patient stories, and the annual GeneSight Mental Health Monitor survey. The company also offers interest-free payment plans and a needs-based financial assistance program.

Name

Assurerx Health

Legal name

Assurex Health, Inc.

Website

https://genesight.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

251–500 employees

Short description

Assurex Health (dba Myriad Neuroscience) develops the GeneSight pharmacogenomic test portfolio, which analyzes genetic variations to help prescribers select and dose mental health medications, serving over 25,000 U.S. healthcare providers from its CLIA/CAP-accredited laboratory in Mason, Ohio.

Ownership category

akta.pro rank

Product category

Pharmacogenomic Testing Services

NAICS

Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071)

akta.pro industry

PRIMARYHLAAANAB

Pharmacogenomics (PGx) Decision Support

Healthcare & Life Sciences/Biotechnology & Biologics/Precision Medicine Solutions

Keywords

• Pharmacogenomic testing
• Mental health diagnostics
• Clinical laboratory services
• Genetic medication analysis
• Personalized medicine testing

Headquarters

HQ city

Mason

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Laboratory Testing Services: GeneSight generates revenue through providing pharmacogenomic laboratory testing services. The company bills insurance (including Medicare, Medicare Advantage, Medicaid, and commercial plans) for the cost of the GeneSight test. Patients may have out-of-pocket costs based on their insurance coverage, with 98% of patients paying $330 or less. Self-pay option is available at $330 for uninsured patients.
2. Financial Assistance and Payment Plans: The company offers interest-free payment plans for patients with costs of $100 or more, spread over up to 12 months. Financial assistance programs are available based on household income and federal poverty guidelines for patients with or without commercial insurance.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels9 records

Core offering

Assurex Health operates the GeneSight pharmacogenomic testing service, a clinician-ordered DNA test that analyzes how genetic variations affect a patient's metabolism of and response to over 60 mental health medications used to treat depression, anxiety, ADHD, and other psychiatric conditions. Samples are collected via cheek swab either in the provider's office or through the GeneSight at Home patient collection kit, processed at the company's CLIA/CAP-accredited laboratory, and reported back to the prescribing clinician through a secure portal within approximately 3 days. The test is covered by Medicare, Medicare Advantage, Medicaid, TRICARE, and most commercial insurance, with a maximum out-of-pocket cost of $330.

Product overview

Assurex Health (dba Myriad Neuroscience) offers GeneSight, a pharmacogenomic testing platform primarily consisting of two core tests: the GeneSight Psychotropic Test and the GeneSight MTHFR Test. The GeneSight Psychotropic Test analyzes genetic variations affecting medication metabolism and response for over 60 mental health medications used to treat depression, anxiety, ADHD, and other psychiatric conditions. The GeneSight MTHFR Test examines folate metabolism gene variations. An optional GeneSight at Home collection kit enables patients to collect DNA samples remotely for processing at the company's CLIA/CAP accredited laboratory. All tests require clinician ordering and results are delivered through a secure provider portal within approximately 3 days of sample receipt.

Differentiator

Problem solved

Functional benefit

Products and services

• GeneSight Psychotropic Test A clinician-ordered pharmacogenomic test that analyzes clinically important genetic variations in a patient's DNA to inform healthcare providers how the patient may metabolize or respond to medications commonly prescribed to treat depression, anxiety, ADHD, and other psychiatric conditions. The test classifies over 60 mental health medications into three color-coded categories based on gene-drug interactions and is processed at the company's CLIA/CAP-accredited laboratory with a 3-day turnaround.
• GeneSight MTHFR Test A clinician-ordered genetic test that detects variations in the MTHFR gene, an enzyme required to convert folic acid and dietary folate into its active form L-methylfolate, which plays a critical role in neurotransmitter synthesis. Results are intended to inform folate-related treatment decisions in patients with mental health conditions.
• GeneSight at Home Patient Collection Kit A patient self-administered buccal (cheek) swab collection kit that enables individuals to complete the GeneSight sample collection at home after their clinician has ordered the test. The kit includes cotton-tipped swabs, a DNA sample envelope, patient consent form, and a prepaid FedEx return envelope for shipping the sample to the GeneSight laboratory.

Quantifiable outcome

• Patients who received GeneSight testing saved over $1,000 in total annual medication costs compared to traditional approaches
• +6 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Iraq and Afghanistan Veterans of America (IAVA)minorStrategic or Co-development Partner · 31 October 2022IAVA partnered with Myriad Genetics in October 2022 to raise awareness about genetic testing and mental health treatment options available to veterans. The partnership included a live event to educate veterans about pharmacogenomic testing and treatment for mental health conditions. This addresses the pressing concern of clinical depression among veterans, with the U.S. Department of Veterans Affairs declaring suicide prevention among all veterans a priority.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Natera: Genetics-focused diagnostics company (oncology, women's health, organ health) that competes for the same lab-based clinical testing reimbursement and physician-ordering channel.
• Myriad Genetics: Parent company of Assurex Health. Operates a broader genetic testing portfolio (hereditary cancer, prenatal, urology) and provides corporate, billing, and R&D infrastructure that GeneSight sits within.
• Tempus Labs: AI-driven precision medicine company with multi-omic molecular testing; competes for the same clinician mindshare and increasingly for payer contracts in personalized medicine.
• Invitae: Broad genetic testing services company with a mental health/behavioural health PGx offering; competes with GeneSight via similar clinician channels and reimbursement infrastructure.
• Veracyte: Genomic diagnostics company with an established urology/oncology franchise now expanding into mental health and other indications via acquisitions; adjacent to GeneSight's specialty diagnostic testing model.

Direct peers

• Genomind: Direct competitor offering a pharmacogenomic test (Genecept Assay) targeting psychiatrists and mental health prescribers — the closest 1:1 analog to GeneSight in mental health PGx.

Emerging players

• Color Health: Population-scale genetic testing company working with health plans and employers; overlaps with GeneSight on clinical genetic testing and employer/payer channel strategy.
• 23andMe: Consumer-facing genetic testing company with a therapeutic R&D arm; overlaps with GeneSight on consumer awareness of genetic health information, though business models differ.

Others

• Foundation Medicine (Roche): Broad incumbent in genomic profiling, primarily oncology, illustrating the scale of large clinically validated genomic testing platforms that pressure smaller specialty PGx labs on evidence standards.
• Mayo Clinic Laboratories: Reference lab arm of Mayo Clinic, an early Assurex Health investor and validation partner; competes for esoteric clinical PGx send-out volume and shapes clinical guideline perception of PGx testing.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/AssurexHealth
• YouTubeyoutube.com/c/genesight
• Facebookfacebook.com/assurexhealth
• LinkedInlinkedin.com/company/assurerx-health-inc
• Instagraminstagram.com/GeneSight

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds10 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Assurerx Health